RA Capital Management
Boston crossover biotech fund; co-invested in CellCentric's £170m Series D.
Last refreshed: 13 May 2026
Timeline for RA Capital Management
CellCentric raises Europe's largest 2026 biotech round
UK Startups and Innovation- What is RA Capital Management?
- RA Capital is a Boston crossover biotech investment firm founded in 2001, investing in clinical-stage life sciences from private rounds through post-IPO, with a focus on oncology and immunology.Source: RA Capital
- Why is RA Capital investing in UK biotech?
- RA Capital participated in CellCentric's £170m Series D in May 2026. Its crossover model allows it to hold European biotech positions from late-stage private financing through a future IPO.Source: Lowdown uk-startups-and-innovation U#4
Background
RA Capital Management participated in CellCentric's £170m Series D in May 2026, Europe's largest biotech round of the year, alongside Venrock Healthcare, Pfizer, Fidelity, Sofinnova Partners, HBM Healthcare, and others. CellCentric's Phase III programme for inobrodib in multiple myeloma sits squarely within RA Capital's oncology crossover thesis.
RA Capital Management is a Boston-based healthcare investment firm founded in 2001, focused on life sciences and biotech at the intersection of private and public markets — the classic 'crossover' model. It manages multiple funds including a hedge fund and private VC vehicles, enabling it to hold positions from private financing through post-IPO. RA Capital is known for large concentrated bets in clinical-stage oncology and immunology, and has a deep scientific team that underwrites late-stage clinical risk directly. Its participation in non-US rounds signals its view that European biotech at clinical stage is attractively priced relative to US comparables.